Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.

ABSTRACT:

Purpose

We studied whether adding percent free PSA to total PSA improves prediction of clinically significant prostate cancer and fatal prostate cancer.

Materials and methods

A total of 6,727 men within the intervention arm of PLCO (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) had baseline percent free PSA. Of this cohort, 475 had clinically significant prostate cancer and 98 had fatal prostate cancer. Cumulative incidence and Cox analyses were conducted to evaluate the association between percent free PSA/PSA and clinically significant prostate cancer/fatal prostate cancer. Harrell's C index evaluated predictive ability. Kaplan-Meier analysis assessed survival.

Results

Median follow-up was 19.7 years, median baseline PSA was 1.19 ng/mL, median perce

SUBMITTER: Yim K 

PROVIDER: S-EPMC10894656 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature